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A crystallographic and theoretical study of an (E)-2-Hydroxyiminoethanone 
derivative: prediction of cyclooxygenase inhibition selectivity of stilbenoids by 
MM-PBSA and the role of atomic charge 
Seyed Sajad Hosseini Balef 1, Ann M. Chippindale2, Hamid Irannejad* 1 
1 Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, 
Iran 
2 Department of Chemistry, University of Reading, Whiteknights, Reading, Berks RG6 6AD, UK 
We recently reported that the hydroxyiminoethanone derivative, (E)-OXM, behaves as a highly 
selective COX-1 inhibitor (COX-1 SI= 833), and also an interesting scaffold with unique 
characteristics. In the current study, a comprehensive crystallographic and computational study 
was performed to elucidate its conformational stability and pharmacological activity. Its 
conformational energy was studied at the B3LYP/6-311G** level of theory and compared to the 
single-crystal X-ray diffraction data. In addition, computational studies of three structurally 
different stilbenoid derivatives used as selective COX-1 or COX-2 inhibitors were undertaken to 
predict their COX selectivity potentials. Flexible docking was performed for all compounds at 
the active site of both COX-1 and COX-2 enzymes by considering some of the key residues as 
flexible during the docking operation. In the next step, molecular dynamic simulation and 
binding free energy calculations were performed by MM-PBSA. Final results were found to be 
highly dependent on the atomic charges of the inhibitors and the choice of force field used to 
calculate the atomic charges. The binding conformation of the hydroxyiminoethanone derivative 
is highly correlated with the type of COX isoform inhibited. Our predictive approach can truly 
predict the cyclooxygenase inhibition selectivity of stilbenoid inhibitors. 
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Introduction 
Cyclooxygenase (COX) is a key enzyme associated with inflammation and cell injury, which are 
processes in which many inflammatory mediators are responsible for cell degeneration. 
Prostaglandins are important inflammatory mediators produced by cyclooxygenase and have 
various functions in different tissues, for example, suppression of fever in the central nervous 
system, platelet aggregation and so on. Neuroinflammation is responsible for neurodegerative 
diseases, such as Alzheimer’s and Parkinson’s, in which COX isoforms (COX-1 and COX-2) 
play a vital role in the initiation and progression of the diseases (Kaur, Gill, Bansal, & 
Deshmukh, 2017). 
Cyclooxygenase has two isoforms, namely COX-1 and COX-2, which are active in normal and 
pathologic conditions, respectively, in specific tissues. Many studies have shown that COX-1 
and COX-2 play major roles in the progression of neurological situations initiated by 
neuroinflammation. Selective inhibition of COX-1 has been shown to slow down in the first 
stages of progressive Alzheimer’s disease (Barbalho, Carvalho, Lopes-Cendes, & Maurer-
Morelli, 2016; Calvello et al., 2017; Choi et al., 2013). Moreover, selective COX-2 inhibitors 
have been administered to reduce brain cytokine levels following seizures (Temp et al., 2017). 
Therefore, selectivity in the inhibition of COX isoforms is very important. One of the main 
factors influencing COX inhibition selectivity is the conformation of the inhibitor and its 
conformational flexibility (Irannejad et al., 2015). Only a few studies have been reported in the 
literature which consider the conformation of the inhibitor and its selectivity towards COX 
inhibition. This structure-property relationship has been explored significantly in stilbenoid COX 
inhibitors, in which two aryl rings are attached through an olefinic bond, or any linkage which 
has some degree of rigidity, and favor a preferred stable conformation (Kakuta et al., 2008; 
Uddin, Rao, Rahim, McDonald, & Knaus, 2004; Zheng et al., 2007). Therefore, there is a 
substantial need to perform a comprehensive and extensive study of the relationship between the 
binding conformation and COX inhibition selectivity of stilbene-like structures. 
Recently, we unexpectedly discovered that a 2-hydroxyiminoethanone derivative, (E)-OXM, 
behaves as a highly selective COX-1 inhibitor (IC50 COX-1= 0.12 µM, IC50 COX-2 >100 µM, 
SI >833). This molecule also contains a sulfonylmethyl group which is a COX-2 selective 
pharmacophoric element (Figure 1) (Irannejad, et al., 2015). In the same report, a preliminary 
computational study was performed to compare two states of the molecule, either when rigid or 
flexible, for docking. The results showed that for selective COX-1 inhibition, the molecule has to 
adopt both cisoid and transoid conformations, but for selective COX-2 inhibition only the cisoid 
conformation of the molecule is necessary for binding to the active site of COX-2. Since many 
aspects of COX selective inhibition remain unknown and also several research articles have 
reported similar results with stilbenoid structures containing amide, sulfonamide and olefinic 
units (Figure 2) (Kakuta, et al., 2008; Uddin, et al., 2004; Zheng, et al., 2007), we decided to do a 
comprehensive in-silico study to establish the relationship between  conformation and COX 
selectivity. 
In this extended study, we studied computationally a 2-hydroxyiminoethanone, (E)-OXM, 
together with three different stilbenoids, AMID, SULF and HEXL, previously reported in the 
literature as COX inhibitors (Figure 2). The 2-hydroxyiminoethanone molecule was studied 
structurally by X-ray crystallography to determine its most stable conformation in the solid state 
and then it was optimized at the level of B3LYP/6-311G**. In the next stage, the compounds 
AMID, SULF and HEXL (Figure 2) were flexibly docked into the active sites of COX-1/2, 
while key residues were considered flexible in the enzyme pocket. The best binding 
conformation of each compound was then extracted and input in to molecular dynamic 
simulation for 500 ps. The free energy of binding for each compound was then calculated and 
compared for both isoforms utilizing the MM-PBSA method. 
 
 
Figure 1. Compound (E)-OXM which was recently reported as a highly selective COX-1 inhibitor (IC50 
COX-1= 0.12 µM, IC50 COX-2 >100 µM, SI >833). 
 
 Figure 2. Stilbenoid compounds a) AMID (COX-1 selective, IC50 COX-1= 0.8 µM, IC50 COX-2 >100 
µM), b) SULF (COX-1 selective, IC50 COX-1= 3.2 µM, IC50 COX-2 >100 µM), c) HEXL (COX-2 
selective, IC50 COX-1 >100 µM, IC50 COX-2 = 0.77 µM). 
Methods 
Conformational analysis 
A conformational search was performed by Gaussian 03 with PM3 force field for the two 
dihedral angles, O9-C8-C10-N11 and H-O12-N11-C10 which were scanned in 40 steps of 10 
degrees and 20 steps of 20 degrees, respectively. The best conformer with the lowest energy was 
extracted and used for geometry optimization by DFT calculations at the level of B3LYP/6-
311G** in both vacuum and water.   
Flexible docking 
PDB structure of COX-1/2 isoforms were retrieved from www.rcsb.org with 1Q4G and 3NT1 
codes and used in the whole procedure. Docking was performed by AutoDock 4 and residues 
Arg120, Tyr385 and Ser530 in COX-1 and His90, Arg120, Arg513 and Ser530 in Cox-2 were 
selected to be flexible during the docking simulation (Chaudhary and Aparoy, 2017). The other 
parameters used were the following: Grid center in COX-1: X= 24.917, Y= 34.602, Z= 201.23 
and in COX-2: X= -43.58, Y= -52.702, Z= -19.287, Grid spacing: 0.375, number of points: 60 х 
60 х 60, number of evaluations: 2500000, population size: 150, GA run: 20. The best docking 
pose with the lowest free energy of binding was extracted and chosen for dynamic simulation 
and free energy calculation (Dadashpour et al., 2015). 2D images of ligand-receptor interactions 
were prepared by Discovery Studio Visualizer 4.5.  
Molecular dynamic simulation & Binding free energy calculation 
GROMACS 5.0 was used for the dynamic simulation of compounds in the COX isoforms for 
500 ps in explicit water and the gromos96 43A1 force field was used for topology generation. 
The topology of the ligands was generated by the PRODRG online server and the atomic charges 
were modified using AM1-BCC, calculated by antechamber program of AmberTools 12, or PM3 
and Mulliken atomic partial charges, calculated by Gaussian 09 (Frisch et al., 2009). The 
topology and coordinate files for the protein were generated using the pdb2gmx program of the 
GROMACS package taking parameters from the gromos96 43A1 force field. The coordinate and 
topology files of the protein and the ligands were then merged to obtain the final starting 
structure and topology file for each complex. 
The complex was centered in a dodecahedral periodic box and solvated by the addition of TIP3P 
water molecules. The total charge of the system was then neutralized by addition of sodium and 
chloride ions as required. Sequentially, energy minimization was performed by using the steepest 
descent algorithm. The system was then gradually heated to 300 K and was equilibrated for 200 
ps using the NVT (constant volume and temperature) ensemble with position restraints applied to 
the heavy atoms followed by 200 ps equilibration in the NPT (constant pressure and temperature) 
ensemble at 1 atm. Both temperature and pressure were regulated using the Berendsen algorithm. 
Finally, the full system was subjected to 500 ps MD simulation with a 2 fs time step. The 
temperature and pressure were maintained at 300 K and 1 atm, respectively, using the v-rescale 
temperature and the Parrinello-Rahman pressure coupling method. The short-range non-bonded 
interactions were computed for the atom pairs within the cut-off of 1 nm, while the long-range 
electrostatic interactions were calculated using the Particle-Mesh-Ewald summation method with 
fourth-order cubic interpolation and 1.2 Å grid spacing. All bonds were constrained using the 
parallel LINCS method. 
Finally, the MM-PBSA method for calculating free energies of binding was carried out using the 
g-mmpbsa script introduced by Rashmi Kumari (Kumari, Kumar, Open Source Drug Discovery, 
& Lynn, 2014). The g-mmpbsa tool is an open-source tool written in the C programming 
language and does not depend on any external software. This tool contains all the required 
subroutines from the GROMACS and the APBS packages to calculate the enthalpic components 
of the MM-PBSA interaction (Singh, Awasthi, Pandey, & Dwivedi, 2017). 
 
X-ray structure determination details 
 
Compound (E)-OXM was prepared according to our previous published article (Irannejad, et al., 
2015). Single crystals of this compound were grown by slow evaporation of the ethanol solvent. 
A crystal of (E)-OXM was mounted under Paratone-N oil and flash cooled to 150 K in a stream 
of nitrogen in an Oxford Cryostream cooler. Single-crystal X-ray intensity data (Table 1) were 
collected using a Rigaku Gemini S Ultra diffractometer (Mo Kα radiation (λ = 0.71073 Å)). The 
data were reduced within the CrysAlisPro software (Rigaku, Xcalibur/SuperNova CCD System, 
& formerly Oxford Diffraction, 2012). The structure was solved in the triclinic space group, P-1, 
using the program Superflip (Palatinus and Chapuis, 2007) and all nonhydrogen atoms located. 
Least-squares refinements on F were carried out using the CRYSTALS suite of programs 
(Betteridge, Carruthers, Cooper, Prout, & Watkin, 2003). The nonhydrogen atoms were refined 
anisotropically. Hydrogen atoms could all be located in difference Fourier maps. The hydrogen 
atom in the O(12) –H(1) hydroxide group was refined isotropically.  The remaining hydrogens 
were placed geometrically with a C-H distance of 0.95 Å and a Uiso of 1.2 times the value of 
Ueq of the parent C atom and their positions refined with riding constraints. There is one 
molecule of (E)-OXM in the asymmetric unit, giving rise to two molecules in the unit cell.  Data 
have been deposited at the Cambridge Crystallographic Data Centre, deposit code: CCDC 
1566249. 
Results & discussion 
The ORTEP structure and crystallographic data of compound (E)-OXM are presented in Figure 
3 and Table 1, respectively, and clearly indicate the E-isomeric form of the imine bond in this 
molecule. 
Figure 3. ORTEP structure of compound (E)-OXM (thermal ellipsoids shown at 50% probability); 
Asymmetric unit with labelling scheme. 
Table 1. Crystallographic and structure refinement data of compound (E)-OXM at 150 K. 
Formula C16 H15 N O5 S 
 Mr 333.365 
Crystal System Triclinic  
Space group P -1 
a / Å 6.4993(4) 
b / Å 7.2813(7) 
c / Å 16.7732(12) 
α /° 98.093(7) 
β / ° 95.852(5) 
γ / ° 90.002(6) 
Volume / Å3 781.68(11) 
Dcalc /g cm3 1.416 
Crystal Habit yellow plate 
No. Reflections (I ≤ 3σ(I)), no. 
parameters 
2651, 212 
R factors: R, Rw (%) 5.02, 5.79 
 
The bond lengths and angles in the molecule are as expected for the particular organic groups 
and are given in Tables S2 and S3 in the supplementary material. The torsion angle, C(13)-
C(10)-C(8)-C(7), is 172.8(2)°. The angle between the mean planes of the two benzene rings is 
~87°. Molecules stack on top of each other along the a axis in the packed structure. Hydrogen 
bonding interactions between adjacent molecules O(12)-H(1)...O(9), 2.710(3) Å, are clearly seen 
when the packed structure is viewed along the c axis (Figure 4). Similar values for bond lengths 
and dihedral angles have been reported for symmetrical benzyl monoximes (Klein, Fischer, 
Seichter, Schwarzer, & Weber, 2011). 
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Figure 4. a) View of unit cell of (E)-OXM along the a axis. b) View of unit cell along c axis. Hydrogen 
bonding interactions are shown as dotted lines. 
In order to better understand the conformational stability of (E)-OXM in various situations, 
conformational analysis was performed for the two important dihedral angles, O9-C8-C10-N11 
and H-O12-N11-C10. For this purpose, O9-C8-C10-N11 was scanned every 10 degrees for 40 
steps and H-O12-N11-C10 was scanned for 20 steps of each 20 degrees.  In total, 861 
conformations (41×21) were generated and scanned for their energy values and their 3D 
graphical representation is illustrated in Figure 5, as a potential energy surface diagram. The best 
conformer with the lowest energy as a global minimum (E= -0.12049 a.u.) with dihedral angles 
of O9-C8-C10-N11 = 111° and H-O12-N11-C10 = 160° was selected for the next step, i.e. 
Geometry optimization by DFT calculations at the level of B3LYP/6-311G** in water and 
vacuum.  
 Figure 5. Potential energy surface scan of (E)-OXM for the two dihedral angles, O9-C8-C10-
N11 and H-O12-N11-C10. 
The results of geometry optimization, i.e. output conformations, dihedral angles and their 
energies are summarized in Table 2. As seen in the table, the resulting optimized conformation 
of (E)-OXM in vacuum and in aqueous solution are transoid and the O9-C8-C10-N11 dihedral 
angle (146° and 151° in vacuum and water) has become much larger compared to the 
corresponding angle in the input structure (111°). The torsion angle, C(13)-C(10)-C(8)-C(7), is 
156° in the optimized structure in water and 150° in the optimized structure in vacuum. These 
data show that the computationally optimized (E)-OXM structure in water is very similar to its 
crystallized structure. To resolve this similarity in conformation, the two structures were aligned 
and their RMSD was calculated to be 0.174, which confirms the close similarity between the two 
structures (Figure 6).   
 Table 2. Geometry optimization results for (E)-OXM at the level of B3LYP/6-311G** in water and 
vacuum. Input structure for optimization was based on the results of a potential energy surface scan of the 
two dihedral angles.  
Input conformation 
(O9-C8-C10-N11 
dihedral angle) 
Output conformation (O9-C8-C10-N11 dihedral angle) 
energy (au) 
in water in vacuum 
(E)-OXM 
(111°) 
Transoid (151°) 
-1447.9789865 
Transoid (146°) 
-1447.9550161 
 
 
Figure 6. Alignment of the two molecules for RMSD calculation (RMSD = 0.174). Blue: 
computationally optimized (E)-OXM structure, Green: crystallized (E)-OXM structure. 
Flexible docking was performed for (E)-OXM and also for the compounds SULF, AMID and 
HEXL in the active sites of both COX-1 and COX-2 enzymes. Residues Arg120, Tyr385 and 
Ser530 in COX-1 and His90, Arg120, Arg513 and Ser530 in COX-2 were selected to be flexible 
during docking simulation and the results are summarized in Table 3. It is shown, that of the 
compounds docked into the active sites of both isoenzymes, (E)-OXM is the most selective 
COX-1 inhibitor (ΔGCOX-1 = -9.85, ΔGCOX-2 = -8.43 kcal/mol). These results confirm our 
experimentally determined IC50 and selectivity index reported previously for this compound 
(Irannejad, et al., 2015). Data obtained for the other compounds, SULF, HEXL and AMID, are 
also compatible with the experimentally determined COX selectivity values reported in the 
literature. Compounds SULF and AMID have been reported to be selective COX-1 inhibitors 
and HEXL was shown to be a selective COX-2 inhibitor (Kakuta, et al., 2008; Uddin, et al., 
2004; Zheng, et al., 2007). As seen in Table 3, the calculated binding energy values for SULF 
and AMID support their COX-1 selectivity and those for compound HEXL demonstrate its 
COX-2 selective inhibition. 
Table 3. Binding energy data (kcal/mol) of flexible docking of compounds into the active site of COX-1 
and COX-2. 
Enzyme (E)-OXM SULF AMID HEXL 
COX-1 -9.85 -8.92 -6.94 -8.07 
COX-2 -8.43 -7.98 -6.70 -9.84 
 
The interacting amino acids with (E)-OXM, SULF, AMID and HEXL in the active sites of 
COX-1 or COX-2 are illustrated in Figure 7. As shown in this figure, Tyr385 and Ser530 in the 
active site of COX-1 are involved in hydrogen bonding to the oxygen atom of sulfonyl group in 
(E)-OXM. There are also several pi-alkyl or pi-pi interactions between the hydrophobic amino 
acids (Val349, Val116, Ala527, Leu352, Ile523, Phe531 and Tyr355) and (E)-OXM. 
Interestingly, Arg120 does not have any interactions with (E)-OXM and the hydroxyimino and 
carbonyl groups of (E)-OXM are not bonded to any atoms of the amino acids. Notably, the 
binding conformation of this molecule is transoid and the torsion angle, O9-C8-C10-N11 is 139°.  
Interacting amino acids of COX-1 active site with AMID and SULF are illustrated in Figures 7B 
and 7C. Most of the bonds formed between COX-1 and AMID and SULF are naturally 
hydrophobic originating from non-polar amino acids. Typically, pi-pi or pi-alkyl interactions are 
formed by Leu531, Val116, Val349, Tyr355, Leu384, Phe381 and Ile523 and the two inhibitors 
are in transoid binding conformations. 
The binding conformation of HEXL as a COX-2 selective inhibitor is illustrated in Figure 7D. 
As shown and expected, the sulfonyl group of this molecule is inserted in the allosteric pocket 
and is hydrogen bonded to His90, Phe518 and Ala516. The other interactions are mostly 
hydrophobic by non-polar or aromatic amino acids. 
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Figure 7. 2D image of interacting amino acids with (E)-OXM, SULF, AMID and HEXL with COX-
1/2. A) (E)-OXM in the active site of COX-1. B) SULF in the active site of COX-1. C) AMID 
in the active site of COX-1. D) HEXL in the active site of COX-2. 
 
Table 4. Binding energy data of compound (E)-OXM in kJ/mol calculated by MM-PBSA in the active 
site of COX-1 and COX-2. Atomic charges calculated by B3LYP/6-311G**. 
Enzyme vdw Electrostatic polar solvation SASA Mean Binding 
energy 
COX-1 -183.26 -91.60 266.527 -18.39 -26.72 
COX-2 -180.26 -204.35 372.23 -17.86 -30.27 
 
Table 5. Binding energy data of compounds in kJ/mol calculated by MM-PBSA in the active site of 
COX-1. Atomic charges calculated by AM1-BCC. 
Compound vdw Electrostatic polar solvation SASA Mean Binding 
energy 
(E)-OXM -234.12 -51.15 192.35 -19.31 -112.2 
AMID -171.35 -16.39 93.72 -15.94 -109.98 
SULF -164.54 -67.15 126.47 -17.57 -122.79 
 
Table 6. Binding energy data of compounds in kJ/mol calculated by MM-PBSA in the active site of 
COX-2. Atomic charges calculated by AM1-BCC. 
Compound vdw Electrostatic polar solvation SASA Mean Binding 
energy 
(E)-OXM -204.68 -0.597 140.319 -19.031 -83.9 
AMID -173.20 -23.76 91.26 -17.31 -123.02 
SULF -178.95 -79.31 131.72 -19.51 -146.05 
 
 
 
Table 7. Binding energy data of compounds in kJ/mol calculated by MM-PBSA in the active site of 
COX-2. Atomic charges calculated by PM3. 
Compound vdw Electrostatic polar solvation SASA Mean Binding 
energy 
SULF -157.97 -17.66 93.78 -16.115 -97.97 
AMID -187.60 0.67 64.41 -16.67 -139.19 
HEXL -153.12 -152.63 117.85 -15.88 -203.79 
(E)-OXM -177.31 -58.10 109.87 -17.18 -142.04 
 
Table 8. Binding energy data of compounds in kJ/mol calculated by MM-PBSA in the active site of 
COX-1. Atomic charges calculated by PM3. 
Compound vdw Electrostatic polar solvation SASA Mean Binding 
energy 
SULF -160.08 -42.00 95.42 -17.40 -124.06 
AMID -191.23 -11.02 55.22 -16.12 -163.15 
HEXL -227.55 -106.13 154.47 -20.62 -199.84 
(E)-OXM -232.28 -37.45 106.98 -18.95 -181.70 
 
In the next step, the best docked conformation of each molecule with lowest energy was 
extracted from the flexible docking procedure into the active sites of the COX-1 and COX-2 
enzymes. The top ranked conformation was  inputted into a molecular dynamic simulation as an 
enzyme-inhibitor complex for 500 ps. Atomic charges were calculated by AM1-BCC, PM3 and 
B3LYP/6-311G** and all steps of dynamic simulation and binding free energy calculations were 
performed by mm-pbsa method introduced by Rashmi Kumari (Kumari, et al., 2014). A brief 
description of this method is helpful to understand the relationships between the physicochemical 
parameters used in the method. Essentially, the binding free energy of a complex is calculated 
from the following equation: 
ΔG binding= G complex - (G protein + G ligand) 
Where, Gcomplex is the total free energy of the protein-ligand complex and Gprotein and Gligand are 
the total free energies of the isolated entities. 
For each individual entity (X), free energy can be calculated by: 
Gx = ( EMM ) - TS + ( Gsolvation ) 
Where, EMM is the average molecular mechanics potential energy in vacuum. TS denotes the 
product of the temperature and the entropic contribution and Gsolvation is the free energy of 
solvation.  In addition, 
EMM    =    Ebonded + Enon-bonded      =      Ebonded + ( Evdw + Eelec) 
where, Ebonded  is bonded interactions and Enon-bonded includes both van der Waals (Evdw) and 
electrostatic (Eelec)interactions and are modeled using a Lennard-Jones (LJ) and Coulomb 
potential function, respectively. 
Gsolvation (solvation free energy) is expressed in the following equation: 
Gsolvation= Gpolar + Gnon-polar 
In this equation, Gpolar and Gnon-polar are the electrostatic and non-electrostatic contributions to the 
solvation free energy, respectively. Gnon-polar includes attractive and repulsive forces between 
solvent and solute that are generated by van der Waals’ interactions and cavity formation, 
respectively. 
Gnon-polar = Gcavity + Gvdw 
One of the most widely used non-polar models to estimate the free energy of solvation is the 
solvent accessible surface area (SASA). 
Finally, mean binding energy, average van der Waals’ and electrostatic energies as well as polar 
solvation and SASA non-polar energies were calculated for each compound in both COX 
isoforms. 
Firstly, Mulliken and partial atomic charges calculated at the B3LYP/6-311G** level were used 
for (E)-OXM in a dynamic simulation and binding-energy calculation. The obtained results were 
not favorable and satisfactory since lower ΔG value for the ligand-COX-2complex indicated 
selective COX-2 inhibition for compound (E)-OXM, in contradiction of our experimentally 
reported results (Table 4). In the second approach, we used AM1-BCC charges from 
antechamber program in AMBER Tools 12 to calculate atomic charges and perform the MD 
simulation. In this step, we realized that the charge of an amine group in any molecule that has 
been calculated by an AM1 force field is assigned as a negatively signed number which is 
incorrect since amine groups, when charged, are normally cationic (Tables S6 and S7 in 
supplementary material). Therefore, molecules with an amine group, such as AMID and SULF, 
did not give logical COX-1/COX-2 binding energies and were predicted to be COX-2 selective 
inhibitors, contrary to experimental observations (Tables 5 and 6). Ultimately, a PM3 force field 
was used for the atomic-charges calculation. All compounds gave reasonable and satisfactory 
results in MD simulation and mm-pbsa analysis when using the PM3 force field. The detailed 
binding free energies for all compounds based on the PM3 charges are summarized in Tables 7 
and 8. 
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Figure 8. Short-range Lennard-Jones interaction energies for (E)-OXM in the active site of a) COX-1 and 
b) COX-2. 
Plots of time-variations in Lennard-Jones and electrostatic energies and also in the number of 
hydrogen bonds formed in MD of (E)-OXM in the active site of COX-1 and COX-2 are shown 
in Figures 8, 9 and 10. As seen in Figure 8, Lennard-Jones interactions for (E)-OXM in COX-1 
start at -175 kJ/mol and fall to -260 kJ/mol over 500 ps, with an average energy of -220 kJ/mol. 
The Lennard-Jones interaction energies for (E)-OXM in COX-2 start at -170 kJ/mol and rise 
slightly over 500 ps to -165 kJ/mol (average energy -170 kJ/mol). Clearly the Lennard-Jones 
energies are much lower for (E)-OXM in COX-1 than in COX-2 in 500 ps of MD simulation 
which helps to overall reduction of free energy of binding. 
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Figure 9. Electrostatic energy plot for (E)-OXM during 500 ps of simulation in the active site of a) COX-
1 and b) COX-2. 
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Figure 10. Number of hydrogen bonds formed during 500 ps of simulation of compound (E)-OXM in the 
active site of COX-1 (left diagram) and COX-2 (right diagram). 
Inversely, the electrostatic interaction energies are lower for (E)-OXM in COX-2 than in COX-
1, as is seen in Figure 9. The electrostatic energy in COX-1 starts at -60 kJ/mol with a rapid rise 
within the first 30 ps followed by descending and ascending slopes ending at -25 kJ/mol. During 
500 ps of MD, the electrostatic energy falls below -60 kJ/mol in COX-1 only at two points and 
the average energy value is -40 kJ/mol. The electrostatic energy is more favorable for (E)-OXM 
in COX-2, since it starts at -55 kJ/mol and ends at -80 kJ/mol, with an average value of -60 
kJ/mol. This shows that polar interactions are more common in COX-2 than COX-1. This fact is 
further confirmed by considering the number of hydrogen bonds formed between (E)-OXM and 
the two enzymes. As illustrated in Figure 10, the average numbers of hydrogen bonds formed at 
the COX-1 and COX-2 active sites are 1970 and 2020, respectively. These results are in 
accordance with the fact that COX-1 active site is more hydrophobic than COX-2. 
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Figure 11. Variations of dihedral angles for (E)-OXM during the last 400 ps of MD simulation in both 
COX isoforms. a) Dihedral angle O9-C8-C10-N11 and b) Dihedral angle C7-C8-C10-C13 
Since the COX inhibition selectivity of stilbenoids has been reported in few cases to depend on 
the binding conformation, we aimed to determine the variation in the two important dihedral 
angles in the 2-hydroxyiminoethanone linkage between the two aryl rings. The two key dihedral 
angles are O9-C8-C10-N11 and C7-C8-C10-C13 for the 2-hydroxyiminoethanone bridge 
between the two aryl rings. Variations in the dihedral angles O9-C8-C10-N11 and C7-C8-C10-
C13 during the last 400 ps are illustrated in Figure 11a and 11b, respectively. The conformations 
of (E)-OXM were extracted every 10 ps ignoring the first 100 ps. Each point in these Figures 
represents a specific binding conformation in COX-1 and/or COX-2 active sites. These diagrams 
simply show the significant difference in the (E)-OXM bound conformation between COX-1 and 
COX-2. Both dihedral angles (O9-C8-C10-N11 and C7-C8-C10-C13) are much larger in COX-1 
than in COX-2 and it means that (E)-OXM is almost in the transoid conformation when bound to 
the COX-1 active site and near to cisoid when bound to the COX-2 active site. This finding is in 
accordance with our previously reported study on how binding conformations of stilbenoids 
influence their COX inhibition selectivity (Irannejad, et al., 2015). This finding also led us to the 
conclusion that the presence of pharmacophoric groups specific for COX-2 selective inhibition, 
such as sulfonamide or sulfonylmethyl, in the structure of stilbenoids are not necessary but also 
conformational flexibility and stability is of greater importance. The results can hopefully lead us 
to design novel selective COX-1 or COX-2 stilbenoid inhibitors in the future. 
Conclusion 
In summary, 2-hydroxyiminoethanones are an interesting scaffold with unique geometrical 
properties. In this study, a recently reported COX-1 selective inhibitor with a 2-
hydroxyiminiethanone structure was selected for a comprehensive computational study. X-ray 
crystallography of this compound shows that its (E)-transoid conformation is stable and that 
there is a hydrogen bonding network between molecules in the crystal structure. Geometry 
optimization resulted in the most stable transoid conformation of this molecule. Results of 
flexible docking confirm the experimentally reported COX selectivity data. Moreover, binding 
free energies calculated by the MM-PBSA method are dependent on the type of force field by 
which atomic charges are calculated and the best results are obtained by PM3. Finally, the 
binding conformation of (E)-OXM was assessed throughout the whole molecular dynamic 
simulation period and its COX inhibition selectivity was shown to be conformational and not 
pharmacophoric dependent. 
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